Suanfarma Suanfarma

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of Merrimack Pharmaceuticals.

    Client Virtual Booth

    MERRIMACK PHARMACEUTICALS

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Merrimack Pharmaceuticals
    United_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    One Broadway, 14th floor Cambridge, MA 02142
    Telephone
    Telephone
    617-720-8606
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.merrimack.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/merrimack-pharmaceuticals/
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Merrimack Receives $225 Million Milestone Payment from Ipsen

    Details:

    Ipsen acquired exclusive commercialization rights for the current and potential future Onivyde, a unique encapsulation formulation of irinotecan in a long-circulating liposomal, as a first-line treatment of metastatic adenocarcinoma on the pancreas in the US.


    Lead Product(s): Irinotecan Hydrochloride,Fluorouracil,Calcium Folinate

    Therapeutic Area: Oncology Product Name: Onivyde

    Highest Development Status: ApprovedProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Ipsen

    Deal Size: $1,025.0 million Upfront Cash: $575.0 million

    Deal Type: Acquisition March 27, 2024

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Merrimack Provides Ipsen Report of Results From Phase III RESILIENT Trial Evaluating Onivyde® in Second-Line Monotherapy for Small Cell Lung Cancer

    Details:

    The press release indicates that the “the primary endpoint OS was not met in patients treated with Onivyde (irinotecan) versus topotecan. However, a doubling of the secondary endpoint of objective response rate (ORR) in favor of Onivyde was observed.


    Lead Product(s): Irinotecan Hydrochloride

    Therapeutic Area: Oncology Product Name: Onivyde

    Highest Development Status: Phase IIIProduct Type: Small molecule

    Recipient: Ipsen

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable August 03, 2022

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    fermion-oy-2024-05-13

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search